Ken Drazan (file photo)

Bris­tol My­ers Squibb ices li­cens­ing pact with Ar­se­nal­Bio to draft its de­sign­er T cells in­to the sol­id tu­mor fight

Back in late 2019, South San Fran­cis­co’s Ar­se­nal­Bio un­corked an $85 mil­lion round to kick­start its de­sign­er T cell project with some splashy back­ers on board. Since then, Ar­se­nal went to work: tripling its team, work­shop­ping its prod­uct strat­e­gy and — in its biggest move yet — bring­ing on a ma­jor drug­mak­er to a mul­ti­year li­cens­ing pact.

Ar­se­nal and Bris­tol My­ers Squibb will team up to find, de­vel­op and com­mer­cial­ize tar­get­ed T cell ther­a­pies for sol­id tu­mors as part of a col­lab­o­ra­tion un­veiled Thurs­day. Ar­se­nal will han­dle the ear­ly dis­cov­ery work in the deal while Bris­tol will pay $70 mil­lion up­front with an op­tion to li­cense pre­clin­i­cal can­di­dates and shep­herd them to mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.